Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC
Abivax Shares Continue Climbing After Biotech Firm Moves to Bolster Balance Sheet
Abivax nears $11 billion valuation after fundraising eases M&A pressure
French biotech stock soars 25% after new data on experimental medicine
Abivax inflammatory bowel drug shows benefit in relapsed and non-responding patients
Abivax Shares Plunge After Company Reports Adverse Events in Key Drug Trial
Abivax shares sink after key trial results for inflammatory bowel drug
Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
Abivax's inflammatory bowel drug meets main goal of late stage trial